DOT1L and neoplasm: The DOT1L inhibitor EPZ-5676 reduced tumorsphere formation and ALDH1+ cells in vitro and inhibited tumor-initiating stem cells and metastasis of ALDH1+-derived tumor xenografts in vivo89.